News Releases

Press Releases

  • 5/22/18 7:30 am EDT

    Conference call to be held May 30, 2018 at 4:30 p.m. Eastern time

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reports financial results for the three months ended March 31, 2018 and provides a business update. Management Commentary “During the first quarter of 2018 and in recent weeks, PAVmed has added the groundbreaking EsoCheck technology to its lead product portfolio, continued to advance itsmore...
  • 5/18/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a conference call on Wednesday, May 30, 2018 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennismore...
  • 5/15/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, announced today that its board of directors approved a reduction to the exercise price of its Series Z Warrants (CUSIP number 70387R122) (the “Series Z Warrants”) that trade under the symbol “PAVMZ” on the Nasdaq Capital Market from $3.00 per share to $1.60 per share. Before this reduction takes effect, notice must first be provided tomore...
  • 5/14/18 7:30 am EDT

    PAVmed subsidiary Lucid Diagnostics Inc. secures exclusive worldwide license for EsoCheck

    Rapid, highly accurate, office-based test utilizes a novel, non-invasive cell-sampling device coupled with proprietary DNA biomarkers to detect Barrett’s Esophagus, precursor to the most common and lethal form of esophageal cancer, caused by acid reflux

    First commercial product projected to launch in the U.S. in the first quarter of 2019, eventually targeting up to 50 million at-risk patients

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM, PAVMZ), a highly differentiated, multi-product medical device company, today announced it has finalized a definitive licensing agreement with Case Western Reserve University to develop and commercialize its groundbreaking EsoCheck technology. EsoCheck is a rapid office-based alternative to diagnostic endoscopy that combines a non-invasive cell sampling device with a DNA biomarker test. Together these have beenmore...
  • 5/8/18 7:30 am EDT

    Each Subscription Right Will Entitle Holder to Purchase One New Unit

    Each New Unit Will be Comprised of One Share of Common Stock and One Series Z Warrant

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company has filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018. Under the proposed Rights Offering, the Company will distributemore...
  • 4/24/18 7:30 am EDT

    PAVmed subsidiary to receive exclusive worldwide license to commercialize EsoCheck

    Five-minute, office-based alternative to endoscopy utilizes highly accurate DNA biomarkers to detect Barrett’s Esophagus, the precursor to a common highly lethal form of esophageal cancer

    Will target up to 50 million at-risk patients and an estimated addressable market of several billion dollars

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product medical device company, today announced that it has signed a letter of intent with Case Western Reserve University to commercialize its groundbreaking EsoCheck technology. EsoCheck combines a non-invasive, cell-sampling device with highly accurate DNA biomarkers to detect Barrett’s Esophagus, the primary precursor of esophageal cancer. In a simple five-minutemore...
  • 4/11/18 7:30 am EDT

    Conference call begins at 4:30 p.m. Eastern time today

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today reports financial results for the three and 12 months ended December 31, 2017 and provides a business update. Management Commentary “During the fourth quarter of 2017 and in recent months, PAVmed has continued to advance toward important regulatory and commercial milestones for its lead products,more...
  • 4/5/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced the final results of its previously disclosed offer to exchange each of its Series W Warrants (Nasdaq: PAVMW, the “Series W Warrant”) for 0.5 Series Z Warrants (the “Offer”). The Offer expired at 5:00 p.m. Eastern time on April 2, 2018. According to Continental Stock Transfer & Trust Company, themore...
  • 4/4/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a conference call on Wednesday, April 11, 2018 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition,more...
  • 4/4/18 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced the preliminary results of its previously disclosed offer to exchange each of its Series W Warrants (Nasdaq: PAVMW, the “Series W Warrant”) for 0.5 Series Z Warrants (the “Offer”). The Offer expired at 5:00 p.m. Eastern time on April 2, 2018. Based on the preliminary count by Continental Stock Transfer &more...

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here to view the Annual Report for PAVmed Inc 2017 Annual Meeting